文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠道炎症调节 ACE2 和 TMPRSS2 的表达，并可能与 SARS-CoV-2 相关疾病的发病机制重叠。

Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease.

机构信息

Center for Biostatistics, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York; Icahn Institute for Data Science and Genomic Technology, New York City, New York.

The Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Precision Institute of Immunology, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

Gastroenterology. 2021 Jan;160(1):287-301.e20. doi: 10.1053/j.gastro.2020.09.029. Epub 2020 Sep 25.

DOI:10.1053/j.gastro.2020.09.029
PMID:32980345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7516468/
Abstract

BACKGROUND AND AIMS: The presence of gastrointestinal symptoms and high levels of viral RNA in the stool suggest active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication within enterocytes. METHODS: Here, in multiple, large cohorts of patients with inflammatory bowel disease (IBD), we have studied the intersections between Coronavirus Disease 2019 (COVID-19), intestinal inflammation, and IBD treatment. RESULTS: A striking expression of ACE2 on the small bowel enterocyte brush border supports intestinal infectivity by SARS-CoV-2. Commonly used IBD medications, both biologic and nonbiologic, do not significantly impact ACE2 and TMPRSS2 receptor expression in the uninflamed intestines. In addition, we have defined molecular responses to COVID-19 infection that are also enriched in IBD, pointing to shared molecular networks between COVID-19 and IBD. CONCLUSIONS: These data generate a novel appreciation of the confluence of COVID-19- and IBD-associated inflammation and provide mechanistic insights supporting further investigation of specific IBD drugs in the treatment of COVID-19. Preprint doi: https://doi.org/10.1101/2020.05.21.109124.

摘要

背景和目的：胃肠道症状和粪便中病毒 RNA 水平高提示肠上皮细胞内存在活跃的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）复制。

方法：在这里，我们在多个大型炎症性肠病（IBD）患者队列中研究了 2019 年冠状病毒病（COVID-19）、肠道炎症和 IBD 治疗之间的交叉点。

结果：小肠肠上皮细胞刷状缘上 ACE2 的强烈表达支持 SARS-CoV-2 的肠道感染。常用的 IBD 药物，包括生物制剂和非生物制剂，在未发炎的肠道中对 ACE2 和 TMPRSS2 受体的表达没有显著影响。此外，我们还定义了对 COVID-19 感染的分子反应，这些反应在 IBD 中也更为丰富，表明 COVID-19 和 IBD 之间存在共同的分子网络。

结论：这些数据对 COVID-19 和 IBD 相关炎症的融合产生了新的认识，并提供了支持进一步研究特定 IBD 药物治疗 COVID-19 的机制见解。预印本 doi：https://doi.org/10.1101/2020.05.21.109124.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/b3b39ac39b53/fx2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/4c235a7dbe6f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/a88bef50f4cc/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/b7d9da87f70e/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/70a0e940ed2b/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/79114a2b783b/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/38fbb7be2ba1/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/1b6bd9b83be2/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/ea7aee457dcf/fx3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/1ae1bf4fcf5d/fx4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/0a2be88562de/fx5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/6127b1355c88/fx6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/1e9e5b318295/fx7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/0bf0329fa6f6/fx8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/da94bd08b7a6/fx9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/dffd60ed5dd0/fx10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/ee5bd3f1ab48/fx11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/2b3b187ab120/fx12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/f28ac5fa660d/fx13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/66b367661e4f/fx14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/8113237193c7/fx15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/b3b39ac39b53/fx2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/4c235a7dbe6f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/a88bef50f4cc/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/b7d9da87f70e/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/70a0e940ed2b/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/79114a2b783b/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/38fbb7be2ba1/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/1b6bd9b83be2/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/ea7aee457dcf/fx3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/1ae1bf4fcf5d/fx4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/0a2be88562de/fx5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/6127b1355c88/fx6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/1e9e5b318295/fx7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/0bf0329fa6f6/fx8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/da94bd08b7a6/fx9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/dffd60ed5dd0/fx10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/ee5bd3f1ab48/fx11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/2b3b187ab120/fx12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/f28ac5fa660d/fx13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/66b367661e4f/fx14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/8113237193c7/fx15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c07/7516468/b3b39ac39b53/fx2_lrg.jpg

相似文献

[1]
Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease.

Gastroenterology. 2021-1

[2]
Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection.

Inflammation. 2022-4

[3]
The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection.

Gastroenterology. 2021-1

[4]
Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD.

Inflamm Bowel Dis. 2020-5-12

[5]
Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.

Gastroenterology. 2021-2

[6]
Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients.

Med Hypotheses. 2020-11

[7]
Hypoxia alters the expression of ACE2 and TMPRSS2 SARS-CoV-2 cell entry mediators in hCMEC/D3 brain endothelial cells.

Microvasc Res. 2021-11

[8]
In search of preventive strategies: novel high-CBD extracts modulate ACE2 expression in COVID-19 gateway tissues.

Aging (Albany NY). 2020-11-22

[9]
Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2.

J Med Virol. 2021-9

[10]
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.

mBio. 2021-8-31

引用本文的文献

[1]
Angiotensin‑converting enzyme 2 expression in human tumors: Implications for prognosis and therapy (Review).

Oncol Rep. 2025-9

[2]
Impact of Glucose, Inflammation and Phytochemicals on , and Glucose Transporter Gene Expression in Human Intestinal Cells.

Antioxidants (Basel). 2025-2-21

[3]
Tofacitinib Mitigates the Increased SARS-CoV-2 Infection Susceptibility Caused by an IBD Risk Variant in the PTPN2 Gene.

Cell Mol Gastroenterol Hepatol. 2025

[4]
Altered plasma levels of the SARS-CoV-2-related proteins ACE2 and TMPRSS2 in patients with Crohn's disease.

Sci Rep. 2024-12-5

[5]
Role of Extracellular Vesicles in Crohn's Patients on Adalimumab Who Received COVID-19 Vaccination.

Int J Mol Sci. 2024-8-14

[6]
SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells.

Viruses. 2024-4-19

[7]
De Novo Crohn's Disease Diagnosed in the Setting of Acute SARS-Cov-2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics.

J Pediatr Perinatol Child Health. 2024

[8]
The Multisystem Impact of Long COVID: A Comprehensive Review.

Diagnostics (Basel). 2024-1-24

[9]
Gene coexpression networks reveal a broad role for lncRNAs in inflammatory bowel disease.

JCI Insight. 2024-2-8

[10]
Molecular mechanisms underlying SARS-CoV-2 hepatotropism and liver damage.

World J Hepatol. 2024-1-27

本文引用的文献

[1]
Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections.

iScience. 2020-12-16

[2]
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.

Nat Commun. 2020-7-24

[3]
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Cell. 2020-5-15

[4]
SARS-CoV-2 productively infects human gut enterocytes.

Science. 2020-5-1

[5]
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Lancet. 2020-5-2

[6]
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?

J Crohns Colitis. 2020-9-16

[7]
Management of IBD during the COVID-19 outbreak: resetting clinical priorities.

Nat Rev Gastroenterol Hepatol. 2020-5

[8]
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.

Mil Med Res. 2020-3-13

[9]
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Cell. 2020-3-5

[10]
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.

Drug Dev Res. 2020-3-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索